Rxivist logo

An effective, safe and cost-effective cell-based chimeric vaccine against SARS-CoV2

By zhenguo Cheng, Danhua Zhang, Xiaowen Liu, Jinxin Miao, Jiaoyao wang, Haoran Guo, Wenli Yan, Zhe Zhang, Shuangshuang Lu, Na Zhang, Jingjing Wang, Zhongxian Zhang, Wei Liu, Yi Zhang, Lirong Zhang, Jianzeng Dong, Nicholas R. Lemoine, Yaohe Wang

Posted 20 Aug 2020
bioRxiv DOI: 10.1101/2020.08.19.258244

More than one hundred vaccines against SARS-CoV-2 have been developed and some of them have entered clinical trials, but the latest results revealed that these vaccines still face great challenges. Here, we developed a novel cell-based gp96-Ig-secreting chimeric vaccine which is composed of two viral antigens, the RBD of spike protein, and a truncated nucleocapsid protein that could induce epitope-specific cytotoxic T lymphocytes but low antibody response. Syrian hamsters immunized with the cell-based vaccine produced high level of SARS-CoV-2 specific NAbs and specific T cell immunity which could eliminate RBD-truncated N-expressing cells, without the induction of antibody against N protein and other observed toxicity. This study provides a proof of concept for clinical testing of this safe, effective and cost-effective vaccine against SARS-CoV2 infection. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 405 times
  • Download rankings, all-time:
    • Site-wide: 54,946 out of 118,665
    • In immunology: 1,427 out of 3,315
  • Year to date:
    • Site-wide: 18,436 out of 118,665
  • Since beginning of last month:
    • Site-wide: 51,650 out of 118,665

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)